ABHD11 and diabetes mellitus: Whilst ABHD11 inhibition does not selectively target autoreactive T-cells—similarly to other clinically available agents62—the broad suppression of T-cell activation is sufficient to delay diabetes development in a preclinical model of autoimmunity.